The PCSK9 gene was first identified by virtue of its homology to other genes of the protein convertase
This lack of consensus is further complicated by growing evidence that the current NT-proBNP immunoassays may detect blood proBNP in HF patients, which is caused by the lack of processing of the precursor proBNP by furin and corin protease convertase
present in the circulation (6-8).
The SPIRE-2 study is one of two cardiovascular outcome trials that are part of the SPIRE Phase 3 global clinical development program that will evaluate the investigational Proprotein Convertase
Subtilisin Kexin type 9 inhibitor (PCSK9i) bococizumab in approximately 32,000 patients with high cholesterol.
OSLER (Open-Label Study of Long-Term Evaluation Against LDL Cholesterol) included 4,465 patients who had completed one of a dozen earlier phase II or III studies of evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin kexin type 9 (PCSK9), and were then randomized 2:1 to 1 year of open-label evolocumab administered subcutaneously at either 140 rag every 2 weeks or 420 mg once monthly plus standard lipid lowering, or to standard lipid lowering alone, generally with moderate- or high-dose statins.
Headquarters, Tokyo; President and CEO: Yoshihiko Hatanaka, Astellas) announced that proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitor Repatha SC Injection (generic name: Evolocumab (Genetically Recombination) Injection) 140 mg Syringe has become available in the Japanese market today.
Previously approved by the US FDA, Repatha is a human monoclonal antibody that inhibits proprotein convertase
subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.
The ODYSSEY LONG TERM trial is the largest and longest study of a PCSK9 (proprotein convertase
subtilisin/kexin type 9) inhibitor to report results to date, with roughly 1,900 patient-years of double-blind exposure to alirocumab.
This "gene of rare effect," proprotein convertase
subtilisin/kexin type 9 (PCSK9),  was found to be a contributing factor to profoundly low cholesterol concentrations in some individuals and has made its way from unknown factor to headline grabber, as detailed in a recent Nature news feature (1).
announced that the Phase 3 SPIRE-AI (AutoInjector) trial of the investigational Proprotein Convertase
Subtilisin Kexin type 9 inhibitor (PCSK9i) bococizumab administered with a pre-filled pen met its co-primary endpoints: percent change from baseline in low-density lipoprotein cholesterol (LDL-C) reduction at 12 weeks compared to placebo and proportion of patients successfully operating the pre-filled pen.